irinotecan
Trade name: Camptosar
Small moleculeapproved
Approved
Jun 14, 1996
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is sold under the brand name Camptosar among others. CAMPTOSAR is a topoisomerase inhibitor indicated for: • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. — NCATS
Clinical trial activity
1,733 trials · 775 clinical orgs · 39 marketing orgs
Phase 1
488
Phase 2
1316
Phase 3
264
Phase 4
25
Earliest trial started Nov 1, 1995 (NCT00001495)
Timeline
1990s
- Jan 1, 1995
Earliest Phase 1 Sponsor(trial)
- Jan 1, 1996
Earliest Phase 2 Sponsor(trial)
- Jun 14, 1996
Pharmacia & Upjohn — Earliest FDA Approval
- Jun 14, 1996
Pharmacia & Upjohn — NDA Organization
- Jun 14, 1996
Pfizer — NDA Secondary Org
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
2000s
- Feb 20, 2008
Cipla — Marketing Organization
- Feb 27, 2008
Actavis — Marketing Organization
- Feb 27, 2008
Fresenius — Marketing Organization
- Feb 27, 2008
Hospira — Marketing Organization
- Feb 27, 2008
Sandoz — Marketing Organization
- Feb 27, 2008
Novartis — Marketing Organization
- Apr 21, 2008
Sun Pharmaceuticals — Marketing Organization
- Oct 31, 2008
Pliva — Marketing Organization
- Oct 31, 2008
Barr Laboratories — Marketing Organization
- Nov 21, 2008
Accord Research — Marketing Organization
- Nov 26, 2008
Teva — Marketing Organization
- Dec 24, 2008
West-Ward Pharmaceutical — Marketing Organization
- Jan 28, 2009
Zhejiang Hisun Pharmaceutical Co. Ltd. — Marketing Organization
- Sep 16, 2009
Akorn, Inc. — Marketing Organization
- Sep 16, 2009
Epic Pharma Llc — Marketing Organization
2010s
- Apr 15, 2010
Neopharma — Marketing Organization
- Apr 15, 2010
Innogenix — Marketing Organization
- Apr 15, 2010
US Antibiotics — Marketing Organization
- Apr 15, 2010
Picket Pharms — Marketing Organization
- Apr 15, 2010
Chartwell Pharmaceuticals — Marketing Organization
- Dec 20, 2010
Hikma — Marketing Organization
- May 13, 2011
Mustafa Nevzat Pharmaceuticals — Marketing Organization
- May 13, 2011
Zennova — Marketing Organization
- May 13, 2011
PHARMOBEDIENT — Marketing Organization
- Dec 16, 2011
Hengrui Therapeutics, Inc. — Marketing Organization
- Dec 16, 2011
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. — Marketing Organization
- Feb 14, 2012
Emcure — Marketing Organization
- Oct 22, 2015
Ipsen — NDA Secondary Org
- Oct 22, 2015
Merrimack Pharmaceuticals — NDA Secondary Org
- Oct 22, 2015
Ipsen — Marketing Organization
- May 3, 2016
Qilu Pharmaceutical Co., Ltd. — Marketing Organization
- May 26, 2017
Ingenus Pharmaceuticals — Marketing Organization
- May 26, 2017
Novast Labs — Marketing Organization
- Aug 31, 2017
Intas Pharmaceuticals Limited — Marketing Organization
- Dec 28, 2018
Shilpa Medicare Ltd. — Marketing Organization
- Nov 18, 2019
Gland Pharma Ltd — Marketing Organization
- Nov 18, 2019
Fosun — Marketing Organization
2020s
- Nov 3, 2020
Eugia Pharma — Marketing Organization
Indications
Studied for
- Adenocarcinoma · Phase 3
- Adenocarcinoma, Mucinous · Phase 1
- Adenoma, Islet Cell · Phase 2
- Adolescent · Phase 2
- Angiogenesis Modulating Agents · Phase 2
- Antibody-Dependent Cell Cytotoxicity · Phase 2
- Antineoplastic Agents · Phase 3
- Antineoplastic Combined Chemotherapy Protocols · Phase 2
- Anus Neoplasms · Phase 1
- Appendiceal Neoplasms · Phase 1
- Appendix · Phase 1
- Ascorbic Acid · Phase 3
- Astrocytoma · Phase 2
- Basal Cell Carcinoma · Phase 2
- Bile Duct Neoplasms · Phase 2/Phase 3
- Biliary Tract Neoplasms · Phase 2
- Biopsy, Large-Core Needle · Phase 2
- Bone Neoplasms · Phase 2
- Brain Diseases · Phase 1
- Brain Neoplasms · Phase 3
- BRCA1 Protein · Phase 1
- Breast Neoplasms · Phase 3
- Burkitt Lymphoma · Phase 1
- Capecitabine · Phase 2
- Carcinoma · Phase 3
- Carcinoma, Adenoid Cystic · Phase 1
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Islet Cell · Phase 2
- Carcinoma, Mucoepidermoid · Phase 1
- Carcinoma, Neuroendocrine · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 4
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Pancreatic Ductal · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 3
- Carcinoma, Transitional Cell · Phase 1
- Carcinoma, Verrucous · Phase 2
- Central Nervous System Neoplasms · Phase 2
- Child · Phase 2
- Cholangiocarcinoma · Phase 3
- Chondrosarcoma · Phase 1
- Choroid Plexus Neoplasms · Phase 3
- Cognition Disorders · Phase 1/Phase 2
- Colonic Neoplasms · Phase 4
- Colorectal Neoplasms · Phase 4
- Craniopharyngioma · Phase 2
- Cytoreduction Surgical Procedures · Phase 2
- Dermatology · Phase 2
- Desmoplastic Small Round Cell Tumor · Phase 1/Phase 2
- Diabetes Mellitus, Type 2 · Phase 4
- Diarrhea · Phase 3
- Diffuse Intrinsic Pontine Glioma · Phase 1/Phase 2
- Digestive System Diseases · Phase 1/Phase 2
- Digestive System Neoplasms · Phase 3
- Disease Progression · Phase 2
- DNA Mismatch Repair · Phase 2
- Docetaxel · Phase 2/Phase 3
- Drug Misuse · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Drugs, Investigational · Phase 3
- Drug Therapy · Phase 3
- Drug Therapy, Combination · Phase 2
- Duodenal Neoplasms · Phase 1
- Endocrine Gland Neoplasms · Phase 1/Phase 2
- Endocrine System Diseases · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Ependymoma · Phase 2
- ErbB Receptors · Phase 2
- Esophageal Neoplasms · Phase 4
- Esophageal Squamous Cell Carcinoma · Phase 3
- Exanthema · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Fluorouracil · Phase 2/Phase 3
- Gallbladder Neoplasms · Phase 2
- Ganglioglioma · Phase 1
- Ganglioneuroblastoma · Phase 3
- Ganglioneuroma · Phase 1
- Gastrointestinal Neoplasms · Phase 3
- Gastrointestinal Stromal Tumors · Phase 1
- General Surgery · Phase 3
- Genes, erbB-2 · Phase 2
- Genes, ras · Phase 2
- Glioblastoma · Phase 2/Phase 3
- Glioma · Phase 2
- Gliosarcoma · Phase 2
- Graft vs Host Disease · Phase 2
- Granuloma · Phase 1
- Hamartoma · Phase 2/Phase 3
- Head and Neck Neoplasms · Phase 2
- Hemangiosarcoma · Phase 2
- Hepatoblastoma · Phase 3
- Hodgkin Disease · Phase 1
- Immunotherapy · Phase 2
- Intestinal Neoplasms · Phase 4
- Intraocular Lymphoma · Phase 1
- Irinotecan · Phase 2/Phase 3
- Kidney Diseases · Phase 2
- Kidney Neoplasms · Phase 2
- Leukemia · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia-Lymphoma, Adult T-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Liposarcoma · Phase 1/Phase 2
- Liver Diseases · Phase 2
- Liver Neoplasms · Phase 3
- Lung Neoplasms · Phase 3
- Lymphoma · Phase 2
- Lymphoma, AIDS-Related · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Large-Cell, Anaplastic · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Lymphoma, T-Cell · Phase 1/Phase 2
- Lymphomatoid Granulomatosis · Phase 1
- Medulloblastoma · Phase 2
- Melanoma · Phase 1
- Meningioma · Phase 2
- Mesothelioma · Phase 1
- Mesothelioma, Malignant · Phase 1/Phase 2
- Microsatellite Instability · Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Mutation · Phase 3
- Nasopharyngeal Carcinoma · Phase 2
- Nasopharyngeal Neoplasms · Phase 2
- Nausea · Phase 2
- Neoadjuvant Therapy · Phase 3
- Neoplasm Metastasis · Phase 3
- Neoplasm Recurrence, Local · Phase 3
- Neoplasms, Basal Cell · Phase 1/Phase 2
- Neoplasms, Bone Tissue · Phase 3
- Neoplasms by Histologic Type · Phase 3
- Neoplasms, Connective and Soft Tissue · Phase 3
- Neoplasms, Connective Tissue · Phase 3
- Neoplasms, Germ Cell and Embryonal · Phase 2
- Neoplasms, Glandular and Epithelial · Phase 1/Phase 2
- Neoplasms, Second Primary · Phase 2
- Neoplasms, Unknown Primary · Phase 3
- Neoplastic Syndromes, Hereditary · Phase 2
- Neuroblastoma · Phase 3
- Neuroectodermal Tumors · Phase 2
- Neuroendocrine Tumors · Phase 4
- Neutropenia · Phase 1
- Oligodendroglioma · Phase 2
- Optic Nerve Glioma · Phase 1/Phase 2
- Organoids · Phase 2
- Oropharyngeal Neoplasms · Phase 1
- Osteosarcoma · Phase 2
- Ovarian Diseases · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Oxaliplatin · Phase 2/Phase 3
- Pancreatectomy · Phase 3
- Pancreatic Diseases · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 3
- Papilloma, Inverted · Phase 1
- Penile Neoplasms · Phase 2
- Peritoneal Neoplasms · Phase 3
- Pharmacological and Toxicological Phenomena · Phase 2
- Pinealoma · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Progression-Free Survival · Phase 2
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Proto-Oncogene Proteins B-raf · Phase 2
- Proto-Oncogene Proteins p21(ras) · Phase 1/Phase 2
- Pseudomyxoma Peritonei · Phase 1
- Radiation · Phase 3
- Radiotherapy · Phase 2
- Rare Diseases · Phase 3
- ras Proteins · Phase 2
- Rectal Neoplasms · Phase 3
- Recurrence · Phase 3
- Rhabdoid Tumor · Phase 1/Phase 2
- Rhabdomyosarcoma · Phase 3
- Rhabdomyosarcoma, Alveolar · Phase 3
- Rhabdomyosarcoma, Embryonal · Phase 3
- Safety · Phase 2
- Salivary Gland Neoplasms · Phase 1
- Sarcoma · Phase 3
- Sarcoma, Ewing · Phase 3
- Sepsis · Phase 1/Phase 2
- Sezary Syndrome · Phase 1
- Small Cell Lung Carcinoma · Phase 4
- Spinal Cord Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 4
- Thrombocytopenia · Phase 2
- Tongue Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Urethral Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 3
- Uterine Diseases · Phase 1/Phase 2
- Wilms Tumor · Phase 3
Mechanism of action
- DNA topoisomerase IINHIBITOR
TOP1 inhibitor
Approval history
- approvedPriority reviewAcceleratedJun 14, 1996
Chemistry & pharmacology
Loading structure…
SMILES
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O- Mol. weight
- 677.19 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Black box warningProdrug
Sources
- ChEMBLCHEMBL3989514 ↗
- WikipediaIrinotecan ↗
- NCATS7673326042 ↗
- ChEMBLCHEMBL541887 ↗
- ChEMBLCHEMBL1200512 ↗
- ChEMBLCHEMBL3039564 ↗
- ChEMBLCHEMBL5314381 ↗
- ChEMBLCHEMBL481 ↗
Also known as
- 7-ethyl-10-hydroxycamptothecin
- 7-ethyl-10-hydroxycamptothecin
- bax2398
- bax2398
- biotecan
- biotecan
- campto
- campto
- campto
- camptosar
- camptosar
- camptosar
- camptosar
- camptosar
- camptothecin-11
- camptothecin-11
- camptothecin-11
- camptothecin-11
- camptothecine
- camptothecine
- (+)-camptothecine
- (+)-camptothecine
- cpt 11
- cpt 11
- cpt-11
- cpt-11
- cpt-11
- d-camptothecin
- d-camptothecin
- ezn-2208
- ezn-2208
- folfiri
- folfiri
- folfirinox
- irinotecan
- irinotecan
- irinotecan
- irinotecan
- irinotecan
- irinotecan
- irinotecan
- irinotecan
- irinotecan
- irinotecan hcl
- irinotecan hcl
- irinotecan hcl
- irinotecan hydrochloride
- irinotecan hydrochloride
- irinotecan hydrochloride
- irinotecan hydrochloride
- irinotecan hydrochloride
- irinotecan hydrochloride hydrate
- irinotecan hydrochloride hydrate
- irinotecan hydrochloride hydrate
- irinotecan hydrochloride trihydrate
- irinotecan hydrochloride trihydrate
- irinotecan hydrochloride trihydrate
- irinotecan liposome
- irinotecan liposome injection
- irinotecan liposome injection
- irinotecan liposome injection
- irinotecan liposome injection
- irinotecan liposome injection
- irinotecan sucrosofate
- irinotecan sucrosofate
- irinotecan sucrosofate
- irrinotecan
- liposomal cpt-11
- liposomal irinotecan
- mm-398
- mm-398
- mm-398
- nanoliposomal irinotecan
- nk012 compound
- onivyde
- pep02
- pep02
- pep-02
- pep-02
- pep02 compound
- (s)-camptothecin
- (s)-camptothecin
- (s)-(+)-camptothecin
- (s)-(+)-camptothecin
- sn 38
- sn-38
- sn-38
- sn-38
- sn 38 11
- sn-38-11
- sn38 cpd
- u-101440e
- u-101440e
- u-101440e
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07271355 | Phase 3 | Jul 1, 2026 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT07283705 | Phase 2 | May 18, 2026 | Bristol-Myers Squibb, University of Texas at Houston |
| NCT07221357 | Phase 2/Phase 3 (Phase 3) | Mar 4, 2026 | Biontech, Bristol-Myers Squibb |
| NCT06998940 | Phase 3 | Jan 6, 2026 | National Cancer Institute (NCI), SWOG Cancer Research Network |
| NCT07004413 | Phase 3 | Jan 1, 2026 | Humboldt University |
| NCT07141771 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Chinese Academy of Medical Sciences |
| NCT07255404 | Phase 2 | Dec 31, 2025 | Biontech, Bristol-Myers Squibb |
| NCT07150403 | Phase 2 | Dec 31, 2025 | Federation Francophone de Cancerologie Digestive |
| NCT07229846 | Phase 2 | Dec 31, 2025 | Harbin Medical University |
| NCT07155200 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Biosplice Therapeutics, Washington University in St. Louis |
| NCT07238283 | Phase 3 | Dec 31, 2025 | Hengrui Therapeutics, Inc. |
| NCT07277842 | Phase 3 | Dec 29, 2025 | Sun Yat-Sen University |
| NCT07258147 | Phase 2 | Dec 25, 2025 | Sichuan University |
| NCT07235202 | Phase 1/Phase 2 (Phase 2) | Dec 22, 2025 | Government of China |
| NCT07284134 | Phase 3 | Dec 20, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT07214298 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2025 | State University of New York, Buffalo |
| NCT07033689 | Early Phase 1 (Phase 1) | Dec 1, 2025 | SONIRE Therapeutics Inc., Stanford University |
| NCT07030283 | Phase 1 | Dec 1, 2025 | University of Colorado, Denver |
| NCT07094893 | Phase 4 | Nov 15, 2025 | Gruppo Oncologico del Nord-Ovest, Merck Serono |
| NCT07085338 | Phase 2 | Nov 10, 2025 | St. Jude Children's Hospital |
Showing 20 of 1,733 trials
Page 1 / 87
Organizations
Research & Development (775)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 283 | 121 | 5 | 1995 |
| Fudan University | Academic/Hospital | 70 | 60 | 5 | 2008 |
| Sun Yat-Sen University | Academic/Hospital | 62 | 53 | 4 | 2011 |
| Pfizer | For profit | 54 | 20 | 4 | 2001 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 48 | 28 | 5 | 2009 |
| Roche | For profit | 48 | 17 | 4 | 2001 |
| Cornell University | Academic/Hospital | 40 | 29 | 3 | 1997 |
| Harvard University | Academic/Hospital | 35 | 23 | 3 | 1998 |
| University of Texas at Houston | Academic/Hospital | 35 | 25 | 3 | 1997 |
| Amgen | For profit | 34 | 13 | 3 | 2002 |
| Sanofi | For profit | 34 | 10 | 3 | 2000 |
| Genentech | For profit | 31 | 8 | 3 | 2003 |
| Bristol-Myers Squibb | For profit | 30 | 13 | 3 | 2001 |
| Merck | For profit | 27 | 16 | 3 | 2004 |
| Zhejiang University | Academic/Hospital | 26 | 22 | 3 | 2009 |
| Federation Francophone de Cancerologie Digestive | Academic/Hospital | 25 | 20 | 2 | 1998 |
| Peking University | Academic/Hospital | 25 | 21 | 5 | 2009 |
| Mayo Clinic | Academic/Hospital | 24 | 4 | 3 | 1997 |
| Jiao Tong University | Academic/Hospital | 22 | 14 | 5 | 2009 |
| Ipsen | For profit | 20 | 4 | 3 | 2015 |
775 organizations
Page 1 / 39
Marketing (48)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Accord Research | For profit | MKTG | Nov 21, 2008 |
| Actavis | For profit | MKTG | Feb 27, 2008 |
| Akorn, Inc. | For profit | MKTG | Sep 16, 2009 |
| Barr Laboratories | For profit | MKTG | Oct 31, 2008 |
| Chartwell Pharmaceuticals | For profit | MKTG | Apr 15, 2010 |
| Cipla | For profit | MKTG | Feb 20, 2008 |
| Emcure | For profit | MKTG | Feb 14, 2012 |
| Epic Pharma Llc | For profit | MKTG | Sep 16, 2009 |
| Eugia Pharma | For profit | MKTG | Nov 3, 2020 |
| Fosun | For profit | MKTG | Nov 18, 2019 |
| Fresenius | For profit | MKTG | Feb 27, 2008 |
| Gland Pharma Ltd | For profit | MKTG | Nov 18, 2019 |
| Gland Pharma Ltd | For profit | SYN | Nov 18, 2019 |
| Hengrui Therapeutics, Inc. | For profit | MKTG | Dec 16, 2011 |
| Hengrui Therapeutics, Inc. | For profit | SYN | Dec 16, 2011 |
| Hikma | For profit | MKTG | Dec 20, 2010 |
| Hikma | For profit | SYN | Dec 24, 2008 |
| Hospira | For profit | MKTG | Feb 27, 2008 |
| Ingenus Pharmaceuticals | For profit | MKTG | May 26, 2017 |
| Innogenix | For profit | MKTG | Apr 15, 2010 |
| Intas Pharmaceuticals Limited | For profit | MKTG | Aug 31, 2017 |
| Ipsen | For profit | NDA2 | Oct 22, 2015 |
| Ipsen | For profit | MKTG | Oct 22, 2015 |
| Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. | For profit | MKTG | Dec 16, 2011 |
| Merrimack Pharmaceuticals | For profit | NDA2 | Oct 22, 2015 |
| Mustafa Nevzat Pharmaceuticals | For profit | MKTG | May 13, 2011 |
| Neopharma | For profit | MKTG | Apr 15, 2010 |
| Novartis | For profit | MKTG | Feb 27, 2008 |
| Novast Labs | For profit | MKTG | May 26, 2017 |
| PHARMOBEDIENT | For profit | MKTG | May 13, 2011 |
| Pfizer | For profit | NDA2 | Jun 14, 1996 |
| Pharmacia & Upjohn | For profit | NDA | Jun 14, 1996 |
| Picket Pharms | For profit | MKTG | Apr 15, 2010 |
| Pliva | For profit | MKTG | Oct 31, 2008 |
| Qilu Pharmaceutical Co., Ltd. | For profit | SYN | May 3, 2016 |
| Qilu Pharmaceutical Co., Ltd. | For profit | MKTG | May 3, 2016 |
| Qilu Pharmaceutical Co., Ltd. | For profit | MKTG | May 3, 2016 |
| Sandoz | For profit | MKTG | Feb 27, 2008 |
| Sandoz | For profit | SYN | Nov 12, 2009 |
| Shilpa Medicare Ltd. | For profit | MKTG | Dec 28, 2018 |
| Shilpa Medicare Ltd. | For profit | MKTG | Dec 28, 2018 |
| Sun Pharmaceuticals | For profit | MKTG | Apr 21, 2008 |
| Teva | For profit | SYN | Feb 27, 2008 |
| Teva | For profit | MKTG | Nov 26, 2008 |
| US Antibiotics | For profit | MKTG | Apr 15, 2010 |
| West-Ward Pharmaceutical | For profit | MKTG | Dec 24, 2008 |
| Zennova | For profit | MKTG | May 13, 2011 |
| Zhejiang Hisun Pharmaceutical Co. Ltd. | For profit | MKTG | Jan 28, 2009 |